U.S. Markets close in 1 hr 41 mins
  • S&P 500

    4,704.54
    +15.87 (+0.34%)
     
  • Dow 30

    35,870.95
    -60.10 (-0.17%)
     
  • Nasdaq

    15,993.71
    +72.14 (+0.45%)
     
  • Russell 2000

    2,363.59
    -13.42 (-0.56%)
     
  • Gold

    1,861.20
    -0.20 (-0.01%)
     
  • Silver

    24.88
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1369
    -0.0006 (-0.0568%)
     
  • 10-Yr Bond

    1.5890
    -0.0150 (-0.94%)
     
  • Vix

    17.59
    +0.48 (+2.81%)
     
  • GBP/USD

    1.3497
    -0.0003 (-0.0216%)
     
  • USD/JPY

    114.3040
    +0.0520 (+0.0455%)
     
  • BTC-USD

    57,871.51
    -465.00 (-0.80%)
     
  • CMC Crypto 200

    1,402.14
    -65.80 (-4.48%)
     
  • FTSE 100

    7,255.96
    -35.24 (-0.48%)
     
  • Nikkei 225

    29,683.09
    +84.43 (+0.29%)
     

Industry Analysts Just Upgraded Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts By 95%

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Celebrations may be in order for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts have sharply increased their revenue numbers, with a view that IDEAYA Biosciences will make substantially more sales than they'd previously expected.

Following the upgrade, the most recent consensus for IDEAYA Biosciences from its seven analysts is for revenues of US$40m in 2021 which, if met, would be a huge 341% increase on its sales over the past 12 months. Losses are predicted to fall substantially, shrinking 28% to US$1.29. Yet prior to the latest estimates, the analysts had been forecasting revenues of US$20m and losses of US$1.31 per share in 2021. So there's definitely been a change in sentiment in this update, with the analysts upgrading next year's revenue estimates, while at the same time holding losses per share steady.

Check out our latest analysis for IDEAYA Biosciences

earnings-and-revenue-growth
earnings-and-revenue-growth

The Bottom Line

The highlight for us was that the consensus reduced its estimated losses next year, perhaps suggesting IDEAYA Biosciences is moving incrementally towards profitability. Given that analysts appear to be expecting substantial improvement in the sales pipeline, now could be the right time to take another look at IDEAYA Biosciences.

These earnings upgrades look like a sterling endorsement, but before diving in - you should know that we've spotted 3 potential flags with IDEAYA Biosciences, including dilutive stock issuance over the past year. For more information, you can click through to our platform to learn more about this and the 2 other flags we've identified .

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.